News
Public · Published
Contineum Therapeutics, Inc. expected to post a loss of 45 cents a share - Earnings Preview
Contineum Therapeutics is expected to report no change in quarterly revenue for the period ending September 30, 2026. Analysts expect a loss of 45 cents a share, and the average rating is buy with a $22.00 median price target.
Published:
Updated:
What happened
Contineum Therapeutics is expected to report no change in quarterly revenue for the period ending September 30, 2026. Analysts expect a loss of 45 cents a share, and the average rating is buy with a $22.00 median price target.
Confirmed
Global impact / market context
A expected loss of 45 cents a share means the company is likely spending more than it earns, which can reduce cash available over time. The buy rating and $22.00 price target suggest analysts see recovery potential despite losses.
Analyst inference
The median price target of $22.00 is about 164.7% above the last closing price of $8.31, meaning analysts see large potential upside. Past results show mixed beats and misses, so investors may expect volatility around earnings.
Analyst inference
What to watch
- Watch whether revenue shows no change versus the prior-year quarter, as the estimate suggests, and whether the loss matches the expected 45 cents a share. Confirmed
- Watch for any change in the mix of analyst ratings, since six buyers and two holders currently shape expectations for the stock's direction. Analyst inference
- Watch how the company manages spending and cash use, since repeated losses can influence future capital spending and the ability to fund operations. Proposed
Evidence
- Original source link unavailable